Genelux Corporation to Participate in Upcoming Conferences
Rhea-AI Summary
Genelux (NASDAQ: GNLX) will participate in two investor conferences in late February and early March 2026. Management will deliver a virtual fireside chat on Feb 25, 2026 at 11:20 a.m. ET and a live presentation on Mar 2, 2026 at 2:30 p.m. ET in Boston.
Live webcasts and archived replays will be available on the company’s Events & Presentations investor relations webpage.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves, with some up and others down; only IOBT appeared on the momentum scanner, moving up, which does not align with GNLX’s slight pre-news decline.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Investor conference | Neutral | -5.4% | Announcement of a virtual fireside chat with Titan Partners. |
| Jan 08 | Equity offering priced | Negative | -19.8% | Pricing of $20M underwritten common stock offering at $3.00. |
| Jan 07 | Equity offering proposed | Negative | +0.0% | Announcement of proposed underwritten public stock offering under shelf. |
| Jan 05 | Clinical data update | Positive | -23.5% | Interim Olvi-Vec lung cancer data with notable response and control rates. |
| Jan 02 | Management change | Positive | +4.4% | Appointment of Jason Litten, M.D., as Chief Medical Officer. |
Recent history shows negative reactions to clinical data and equity offerings, while a management hire drew a modestly positive response.
Over the past few months, Genelux has combined clinical updates, financings, and corporate changes. A January conference-related event on Jan 19, 2026 was followed by a -5.36% move. Two January offerings, including a $20.0 million underwritten deal at $3.00, saw pressure, with one day down -19.76%. Encouraging lung cancer interim data on Jan 5, 2026 coincided with a -23.52% reaction, while the CMO appointment on Jan 2, 2026 drew a 4.36% gain. Today’s conference participation fits this pattern of active investor outreach.
Market Pulse Summary
This announcement highlights Genelux’s plan to present at the Oppenheimer Healthcare Life Sciences Conference on February 25, 2026 and the TD Cowen 46th Annual Health Care Conference on March 2, 2026. These events extend the company’s ongoing investor outreach following recent clinical, financing, and management developments. Investors may focus on any incremental clinical details, capital plans, or strategic updates shared in these forums, alongside previously disclosed trial data and recent regulatory filings.
AI-generated analysis. Not financial advice.
WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences.
- Oppenheimer Healthcare Life Sciences Conference: Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat on Wednesday, February 25, 2026, at 11:20 a.m. ET.
- TD Cowen 46th Annual Health Care Conference: Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, Chief Financial Officer, will participate in a presentation on Monday, March 2, 2026, at 2:30 p.m. ET in Boston, MA.
Live webcasts of the fireside chat and presentation can be found on the Events & Presentations section of the Company’s Investor Relations website at https://investors.genelux.com/news-events/events-presentations. Following the completion of the events, an archived replay of each webcast will be available on the Company’s Investor Relations website.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b/2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which Genelux has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
Investor Contact
Austin Murtagh
Precision AQ
austin.murtagh@precisionaq.com
Media Contact
Ashley Murphy
Precision AQ
ashley.murphy@precisionaq.com
Source: Genelux Corporation
FAQ
When will Genelux (GNLX) present at the Oppenheimer Healthcare Life Sciences Conference?
What is the schedule for Genelux (GNLX) at the TD Cowen 46th Annual Health Care Conference?
Who from Genelux (GNLX) will attend the Feb 25 and Mar 2, 2026 investor events?
How can investors watch the Genelux (GNLX) conference webcasts and replays?
Will the Feb 25, 2026 Genelux (GNLX) fireside chat be virtual or in-person?
Does Genelux (GNLX) provide archived replays after its conference presentations?
